Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans

Diabetes, Obesity and Metabolism

Volumn 16, Issue 7, 2014, Pages 622-627

  Suzuki, M ^a   Hiramatsu, M ^b   Fukazawa, M ^a   Matsumoto, M ^b   Honda, K ^a   Suzuki, Y ^a   Kawabe, Y ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Research Institute for Medical Science Inc   (Japan)

Author keywords

Antidiabetic drug; Diabetic complications; Experimental pharmacology; Renal glucose handling; SGLT2 inhibitor; Type 2 diabetes; Urinary tract infection

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENITAL CANDIDIASIS; GLUCOSE URINE LEVEL; GLUCOSURIA; INOCULATION; MOUSE; NONHUMAN; TREATMENT DURATION; URINARY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CANDIDIASIS; DRUG EFFECTS; KIDNEY; MICROBIOLOGY; URINARY TRACT INFECTIONS;

ANIMALS; BENZHYDRYL COMPOUNDS; CANDIDA ALBICANS; CANDIDIASIS; DISEASE PROGRESSION; FEMALE; GLUCOSIDES; GLYCOSURIA; KIDNEY; MICE; MICE, INBRED C57BL; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; URINARY TRACT INFECTIONS;

EID: 84903119140     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12259     Document Type: Article

References (27)

1. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26: 510-513.
2. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 2007; 50: 549-554.
3. Muller LM, Gorter KJ, Hak E et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41: 281-288.
4. Nicolle LE. Urinary tract infection in diabetes. Curr Opin Infect Dis 2005; 18: 49-53.
5. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med 2002; 113(Suppl. 1A): 80S-84S.
6. Brown JS, Wessells H, Chancellor MB et al. Urologic complications of diabetes. Diabetes Care 2005; 28: 177-185.
7. Geerlings SE, Brouwer EC, Gaastra W, Verhoef J, Hoepelman AI. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol 1999; 48: 535-539.
8. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet TJ, Hoepelman AI. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000; 23: 1737-1741.
9. Geerlings SE. Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. Int J Antimicrob Agents 2008; 31(Suppl. 1): S54-S57.
10. Prat V, Konickova L, Hatala M, Urbanova D. Evaluation of the antibacterial effect of nalidixic acid in two experimental models of Escherichia coli pyelonephritis. Br J Exp Pathol 1968; 49: 60-67.
11. Tokunaga S, Ohkawa M, Nakamura S. An experimental model of ascending pyelonephritis due to Candida albicans in rats. Mycopathologia 1993; 123: 149-154.
12. Hung CS, Dodson KW, Hultgren SJ. A murine model of urinary tract infection. Nat Protoc 2009; 4: 1230-1243.
13. Rosen DA, Hung CS, Kline KA, Hultgren SJ. Streptozocin-induced diabetic mouse model of urinary tract infection. Infect Immun 2008; 76: 4290-4298.
14. Gaulton GN, Schwartz JL, Eardley DD. Assessment of the diabetogenic drugs alloxan and streptozotocin as models for the study of immune defects in diabetic mice. Diabetologia 1985; 28: 769-775.
15. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28: 1173-1178.
16. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-393.
17. Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012; 28: 1167-1171.
18. Wilding JP, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-415.
19. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
20. Nomura S, Sakamaki S, Hongu M et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010; 53: 6355-6360.
21. Ohtake Y, Sato T, Kobayashi T et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2012; 55: 7828-7840.
22. Umenai T, Suzuki F, Ishida N. Effect of an interferon inducer, 9-methylstreptimidone, on Candida albicans infection in mice. Antimicrob Agents Chemother 1978; 13: 939-943.
23. Vallon V, Rose M, Gerasimova M et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013; 304: F156-F167.
24. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010; 23: 253-273.
25. Suzuki M, Honda K, Fukazawa M et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 2012; 341: 692-701.
26. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
27. Liang Y, Arakawa K, Ueta K et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555.